Clinical Chemistry,
Год журнала:
2024,
Номер
70(1), С. 165 - 178
Опубликована: Янв. 1, 2024
Substantial
research
has
been
devoted
to
elucidating
the
role
of
extracellular
vesicles
(EVs)
in
different
hallmarks
cancer.
Consequently,
EVs
are
increasingly
explored
as
a
source
cancer
biomarkers
body
fluids.
However,
heterogeneity
EVs,
complexity
fluids,
and
diversity
methods
available
for
EV
analysis,
challenge
development
translation
EV-based
biomarker
assays.
Circulation,
Год журнала:
2024,
Номер
149(22), С. 1729 - 1748
Опубликована: Март 15, 2024
Myocardial
infarction
(MI)
and
heart
failure
are
associated
with
an
increased
incidence
of
cancer.
However,
the
mechanism
is
complex
unclear.
Here,
we
aimed
to
test
our
hypothesis
that
cardiac
small
extracellular
vesicles
(sEVs),
particularly
mesenchymal
stromal
cell-derived
sEVs
(cMSC-sEVs),
contribute
link
between
post-MI
left
ventricular
dysfunction
(LVD)
Proceedings of the National Academy of Sciences,
Год журнала:
2025,
Номер
122(4)
Опубликована: Янв. 23, 2025
Heterogeneous
roles
of
complement
C3
have
been
implicated
in
tumor
metastasis
and
are
highly
context
dependent.
However,
the
underlying
mechanisms
linking
to
remain
elusive
renal
cell
carcinoma
(RCC).
Here,
we
demonstrate
that
RCC
cell-derived
extracellular
vesicles
(EVs)
contributes
via
polarizing
tumor-associated
macrophages
(TAMs)
into
immunosuppressive
phenotype
recruiting
polymorphonuclear
myeloid-derived
suppressor
cells
(PMN-MDSCs).
Mechanistically,
EV
induces
secretion
CCL2
CXCL1
by
lung
subsequently
enhances
TAM
polarization
PMN-MDSC
recruitment.
Notably,
targeting
CCL2/CCR2
or
CXCL1/CXCR2
axis
with
inhibitors
RS504393
Navarixin,
respectively,
effectively
suppresses
induced
RCC-derived
a
mouse
model.
Clinically,
patients
high
expression
poor
prognosis.
Collectively,
our
findings
reveal
tumor-derived
an
microenvironment
TAMs,
thus
promoting
metastasis.
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2025,
Номер
44(1)
Опубликована: Фев. 6, 2025
Abstract
Background
Cancer
cells
are
avid
extracellular
vesicle
(EV)
producers.
EVs
transport
transforming
growth
factor-β
(TGF-β),
which
is
commonly
activated
under
late
stages
of
cancer
progression.
Nevertheless,
whether
TGF-β
signaling
coordinates
EV
biogenesis
a
relevant
topic
that
remains
minimally
explored.
Method
We
sought
after
specific
pathway
mediators
could
regulate
release.
To
this
end,
we
used
large
number
cell
models,
coupled
to
biological
assays,
unbiased
proteomic
and
transcriptomic
screens,
followed
by
biology
analyses,
including
drug
resistance
assays.
Results
report
TGF-β,
activating
its
type
I
receptor
MEK-ERK1/2
signaling,
increased
the
numbers
released
human
cells.
Upon
examining
cholesterol
as
mediator
biogenesis,
delineated
whereby
ERK1/2
acted
phosphorylating
sterol
regulatory
element-binding
protein-2
transcriptionally
induced
7-dehydrocholesterol
reductase
expression,
thus
raising
abundance
at
both
cellular
levels.
Notably,
inhibition
MEK
or
synthesis,
impaired
TGF-β-induced
secretion,
sensitized
chemotherapeutic
drugs.
Furthermore,
profiling
two
distinct
populations
revealed
secreted
TGF-β-stimulated
were
either
depleted
enriched
for
different
sets
cargo
proteins.
Among
these,
latent-TGF-β1
present
in
was
not
affected
while
pathway-related
molecules
(e.g.,
matrix
metalloproteinases,
MMP9)
uniquely
on
strongly
enhanced
stimulation.
EV-associated
SMAD
even
when
uptake
blocked
heparin,
indicating
competent
capacity
from
target
surface
receptors.
MMP
inhibitor
proteinase
treatment
EV-mediated
suggesting
require
activity
release
active
latent
complex,
function
also
linked
transfer
pro-migratory
potential
ability
survive
presence
cytotoxic
Conclusion
Hence,
novel
cascade
leads
high
rates
generation
response
with
being
key
intermediate
step
mechanism.
Graphical
•
increases
MEK-ERK1/2-SREBP2-DHCR7
transcriptional
pathway.
DHCR7
expression
raises
promotes
carry
MMP9
can
activate
recipient